Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Effects of Workplace Generalized and Sexual Harassment on Abusive Drinking Among First Year Male and Female College Students: Does Prior Drinking Experience Matter?

Rospenda KM, Fujishiro K, McGinley M, Wolff JM, Richman JA.

Subst Use Misuse. 2017 Jun 7;52(7):892-904. doi: 10.1080/10826084.2016.1267218. Epub 2017 Feb 22.

2.

Therapie des metastasierten kastrationsresistenten Prostatakarzinoms mit Abirateronacetat im klinischen Alltag.

Wolff JM.

Oncol Res Treat. 2017;40 Suppl 2:11-12. doi: 10.1159/000456169. Epub 2017 Apr 3. Review. German.

PMID:
28365709
3.

Risk factors and outcomes of chronic sexual harassment during the transition to college: Examination of a two-part growth mixture model.

McGinley M, Wolff JM, Rospenda KM, Liu L, Richman JA.

Soc Sci Res. 2016 Nov;60:297-310. doi: 10.1016/j.ssresearch.2016.04.002. Epub 2016 Apr 4.

4.

Do MCAT scores predict USMLE scores? An analysis on 5 years of medical student data.

Gauer JL, Wolff JM, Jackson JB.

Med Educ Online. 2016 Sep 30;21:31795. doi: 10.3402/meo.v21.31795. eCollection 2016.

5.

[Strategies for First-Line Treatment of mCRPC].

Miller K, Gschwend J, Wolff JM.

Aktuelle Urol. 2016 Sep;47(5):395-401. doi: 10.1055/s-0042-108533. Epub 2016 Sep 28. Review. German.

PMID:
27680191
6.

Sexual Harassment, Psychological Distress, and Problematic Drinking Behavior Among College Students: An Examination of Reciprocal Causal Relations.

Wolff JM, Rospenda KM, Colaneri AS.

J Sex Res. 2017 Mar-Apr;54(3):362-373. doi: 10.1080/00224499.2016.1143439. Epub 2016 Mar 16.

7.

[Mechanisms of Resistance in Antihormone Therapies of Advanced Prostate Cancer].

Thelen P, Gschwend J, Wolff JM, Miller K.

Aktuelle Urol. 2016 Feb;47(1):79-85. doi: 10.1055/s-0041-108295. Epub 2016 Jan 27. Review. German.

PMID:
26814975
8.

[Testosterone in the management of metastatic prostate cancer].

Wolff JM, Schmid HP.

Urologe A. 2015 Nov;54(11):1578-83. doi: 10.1007/s00120-015-3813-4. Review. German.

PMID:
26113300
9.

Age Differences in the Longitudinal Relationship between Work-Family Conflict and Alcohol Use.

Wolff JM, Rospenda KM, Richman JA.

J Addict. 2014;2014:354767. doi: 10.1155/2014/354767. Epub 2014 Jan 28.

10.

Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?

Wolff JM, Abrahamsson PA, Irani J, da Silva FC.

BJU Int. 2014 Oct;114(4):476-83. doi: 10.1111/bju.12626. Epub 2014 Apr 16. Review.

11.

Bullying victimization among college students: negative consequences for alcohol use.

Rospenda KM, Richman JA, Wolff JM, Burke LA.

J Addict Dis. 2013;32(4):325-42. doi: 10.1080/10550887.2013.849971.

12.

[Value of intermittent androgen deprivation in the context of the current data situation].

Miller K, Hammerer P, Eichenauer R, Geiges G, Lehmann J, Rodemer G, Ruessel C, Rulf W, Suttmann H, Wolff JM.

Aktuelle Urol. 2013 Jul;44(4):271-6. doi: 10.1055/s-0033-1348245. Epub 2013 Jul 25. Review. German.

PMID:
23888406
13.

The role of pubertal timing and temperamental vulnerability in adolescents' internalizing symptoms.

Crockett LJ, Carlo G, Wolff JM, Hope MO.

Dev Psychopathol. 2013 May;25(2):377-89. doi: 10.1017/S0954579412001125.

14.

Work-family conflict and alcohol use: examination of a moderated mediation model.

Wolff JM, Rospenda KM, Richman JA, Liu L, Milner LA.

J Addict Dis. 2013;32(1):85-98. doi: 10.1080/10550887.2012.759856.

15.

Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?

Scully MA, Cwik VA, Marshall BC, Ciafaloni E, Wolff JM, Getchius TS, Griggs RC.

Neurology. 2013 Feb 5;80(6):583-9. doi: 10.1212/WNL.0b013e318282334e. Review.

16.

[Pathophysiology and therapy of castration-resistant prostate cancer].

Merseburger AS, Kuczyk MA, Wolff JM.

Urologe A. 2013 Feb;52(2):219-25. doi: 10.1007/s00120-012-3054-8. Review. German.

PMID:
23160609
17.

The Role of Emotional Reactivity, Self-regulation, and Puberty in Adolescents' Prosocial Behaviors.

Carlo G, Crockett LJ, Wolff JM, Beal SJ.

Soc Dev. 2012 Nov;21(4):667-685. doi: 10.1111/j.1467-9507.2012.00660.x. Epub 2012 Apr 26.

18.

Drivers for change in the management of prostate cancer - guidelines and new treatment techniques.

Wolff JM, Mason M.

BJU Int. 2012 Jun;109 Suppl 6:33-41. doi: 10.1111/j.1464-410X.2012.11218.x. Review.

19.

Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab.

Wolff JM, Schmid HP.

Transl Androl Urol. 2012 Jun;1(2):118-9. doi: 10.3978/j.issn.2223-4683.2012.05.03. No abstract available.

20.

Drinking in the age of the Great Recession.

Richman JA, Rospenda KM, Johnson TP, Cho YI, Vijayasira G, Cloninger L, Wolff JM.

J Addict Dis. 2012;31(2):158-72. doi: 10.1080/10550887.2012.665692.

21.

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.

Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM; TAP22 Investigators Group.

BJU Int. 2012 Nov;110(9):1262-9. doi: 10.1111/j.1464-410X.2012.11120.x. Epub 2012 Apr 13.

22.

Parent and peer pathways to adolescent delinquency: variations by ethnicity and neighborhood context.

Deutsch AR, Crockett LJ, Wolff JM, Russell ST.

J Youth Adolesc. 2012 Aug;41(8):1078-94. doi: 10.1007/s10964-012-9754-y. Epub 2012 Mar 30.

PMID:
22460729
23.

[Intermittent androgen deprivation in advanced prostate cancer: a review].

Wolff JM.

Aktuelle Urol. 2012 Mar;43(2):115-20. doi: 10.1055/s-0031-1283877. Epub 2012 Jan 5. Review. German.

PMID:
22222751
24.

The role of deliberative decision making, parenting, and friends in adolescent risk behaviors.

Wolff JM, Crockett LJ.

J Youth Adolesc. 2011 Dec;40(12):1607-22. doi: 10.1007/s10964-011-9644-8. Epub 2011 Mar 8.

PMID:
21384100
25.

[Systemic treatment of metastatic prostate cancer].

Wörmann B, Wolff JM.

Urologe A. 2010 Feb;49(2):221-7. doi: 10.1007/s00120-010-2238-3. Review. German.

PMID:
20180063
26.

[GnRH antagonists--a new therapy option for advanced prostate cancer].

Wolff JM.

Aktuelle Urol. 2009 May;40(3):159-63. doi: 10.1055/s-0028-1098882. Epub 2009 Apr 27. Review. German.

PMID:
19399720
27.

Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.

Schröder FH, Bangma CH, Wolff JM, Alcaraz A, Montorsi F, Mongiat-Artus P, Abrahamsson PA, McNicholas TA, Castro RS, Nandy IM.

BJU Int. 2009 Mar;103(5):590-6. doi: 10.1111/j.1464-410X.2009.08373.x.

28.

Chemotherapy in hormone-refractory prostate cancer.

Wolff JM.

Front Radiat Ther Oncol. 2008;41:103-7. doi: 10.1159/000139884. Review.

PMID:
18544991
29.
30.

[100 years prostate cancer: yesterday--today--tomorrow].

Budäus LH, Wirth MP, Wolff JM, Bartsch G, Noldus J, Huland H.

Urologe A. 2006 Sep;45 Suppl 4:122-6. German. No abstract available.

PMID:
16823582
31.

[Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma].

Miller K, Becker K, Finke F, Geiges G, Göckel-Beining B, Hossfeld DK, Miller K, Osieka R, Rüssel C, Tesch H, Weissbach L, Wirth M, Wolff JM.

Aktuelle Urol. 2006 May;37(3):201-4. German.

PMID:
16733822
32.

[The role of PSA in diagnosis of prostate cancer and its recurrence].

Vergho DC, Heine K, Wolff JM.

Pathologe. 2005 Nov;26(6):473-8. German.

PMID:
16215709
33.

Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?

Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM.

Urol Int. 2005;75(3):204-8.

PMID:
16215305
34.

[The aftercare principle for metastasizing prostate cancer. Few diagnostics, much support].

Heine K, Wolff JM.

Urologe A. 2005 Sep;44(9):1009-12, 1014-7. Review. German.

PMID:
16096743
35.

[Chemotherapy of the hormone-refractory prostate cancer].

Heine K, Wolff JM.

Aktuelle Urol. 2004 Jun;35(3):209-14. Review. German.

PMID:
15258854
36.

[Urological illnesses in the elderly].

Wolff JM.

Urologe A. 2004 Aug;43(8):916-21. German.

PMID:
15249959
37.

[Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].

Wolff JM.

Onkologie. 2003 Dec;26 Suppl 7:37-40. Review. German.

PMID:
14716141
38.

Urological complications of renal transplantation: a series of 900 cases.

Reek C, Noster M, Burmeister D, Wolff JM, Seiter H.

Transplant Proc. 2003 Sep;35(6):2106-7. No abstract available.

PMID:
14529857
39.

Intermittent androgen ablation as a treatment for prostate cancer.

Wolff JM.

Front Radiat Ther Oncol. 2002;36:66-71. Review. No abstract available.

PMID:
11842756
40.

[Urologic tumors and organ transplantation. Recommendations of the Kidney Transplantation Working Group of the Ongoing Graduate and Continuing Education Committee of the German Society of Urology].

Dreikorn K, Heicapell R, Heynemann H, Klebingat KJ, Reek C, Schönberger B, Seiter H, Wolff JM.

Urologe A. 2001 Nov;40(6):493-4. German. No abstract available.

PMID:
11760358
41.

EAU guidelines on prostate cancer.

Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, Zattoni F; EAU Working Group on Oncological Urology.

Eur Urol. 2001 Aug;40(2):97-101.

PMID:
11528184
42.

Serum levels of prostate specific antigen in men on hemodialysis.

Wolff JM, Ting O, Borchers H, Rohde D, Jakse G.

Anticancer Res. 2000 Nov-Dec;20(6D):5191-3.

PMID:
11326693
43.

Tissue polypeptide specific antigen serum concentrations in patients with newly diagnosed prostatic diseases.

Wolff JM, Rohde D, Borchers H, Jakse G.

Anticancer Res. 2000 Nov-Dec;20(6D):5003-5.

PMID:
11326658
44.

Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.

Hillenbrand M, Bastian M, Steiner M, Zingler C, Müller M, Wolff JM, Seiter H, Schuff-Werner P.

Anticancer Res. 2000 Nov-Dec;20(6D):4995-6.

PMID:
11326656
45.

Are age-specific reference ranges for prostate specific antigen population specific?

Wolff JM, Brehmer B, Borchers H, Rohde D, Jakse G.

Anticancer Res. 2000 Nov-Dec;20(6D):4981-3.

PMID:
11326652
46.

Altered prostate specific antigen reference range after transurethral resection of the prostate.

Wolff JM, Boekels O, Borchers H, Jakse G, Rohde D.

Anticancer Res. 2000 Nov-Dec;20(6D):4977-80.

PMID:
11326651
48.

Interleukin-6: a potential inflammatory marker after total joint replacement.

Wirtz DC, Heller KD, Miltner O, Zilkens KW, Wolff JM.

Int Orthop. 2000;24(4):194-6.

49.

[Expanded, radical perineal prostatectomy].

Jakse G, Manegold E, Reineke T, Borchers H, Brehmer B, Wolff JM, Mittermayer C.

Urologe A. 2000 Sep;39(5):455-62. German.

PMID:
11045048
50.

Intermittent androgen blockade in prostate cancer: rationale and clinical experience.

Wolff JM, Tunn UW.

Eur Urol. 2000 Oct;38(4):365-71. Review.

PMID:
11025372

Supplemental Content

Loading ...
Support Center